OpenOnco · Treatment Plan

Treatment plan — Laryngeal squamous cell carcinoma

PLAN-VERIFIED-LARYNGEAL-L1-LARYNGEAL_LA_1L_CRT-V1 · v1 · 2026-07-15

Patient

VERIFIED-LARYNGEAL-L1-LARYNGEAL_LA_1L_CRT · Algorithm: ALGO-LARYNGEAL-1L

DiagnosisLaryngeal squamous cell carcinoma

MOH / ICD-10C32

ICD-O-38070/3; C32

Etiological driver

Etiological driver · etiologically_driven archetype

Laryngeal squamous cell carcinoma

Tobacco smoking — dominant; >90% attributable in heavy smokers
Alcohol consumption — synergistic with tobacco (multiplicative risk)
Occupational asbestos / nickel / wood-dust exposure (smaller incremental risk)
HPV — small subset of supraglottic SCC (clinically less relevant than HPV+OPSCC)
Prior laryngeal radiation

Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks

Biomarker	Variant	ESCAT	Evidence	Clinical significance	Drugs	Sources
No clinically actionable variants matched in this profile.

Primary current-line option

Local therapy plan

★ DEFAULT

Indication

IND-LARYNGEAL-LA-1L-CRT

Regimen

Cisplatin concurrent with definitive RT (larynx-preservation CRT; RTOG 91-11)

Drugs + NSZU

Cisplatin (DRUG-CISPLATIN) 100 mg/m² IV day 1 (preferred when ECOG 0-1, GFR ≥60, no neuropathy / ototoxicity / heart failure) · Day 1 of each 21-day cycle x3 cycles (days 1, 22, 43), concurrent with a 7-week definitive RT course · IV ⚠ NSZU — not for this indication

Reason

Provisional current-line default from ALGO-LARYNGEAL-1L: step 1 did not select a treatment branch. Histologic confirmation and complete staging workup (direct laryngoscopy/panendoscopy under anesthesia, cross-sectional imaging) required before treatment-pathway selection.

Other current-line alternatives (6 tracks)

Same treatment line; review when biomarker, access, contraindication, or patient-context assumptions change.

Local therapy plan

Indication: IND-LARYNGEAL-EARLY-GLOTTIC-1L-RT
Regimen: —
Reason: Current-line alternative presented for HCP consideration

Local therapy plan

Indication: IND-LARYNGEAL-EARLY-GLOTTIC-1L-TLM
Regimen: —
Reason: Current-line alternative presented for HCP consideration

Local therapy plan

Indication: IND-LARYNGEAL-LA-1L-TOTAL-LARYNGECTOMY
Regimen: —
Reason: Current-line alternative presented for HCP consideration

Standard plan

Indication

IND-LARYNGEAL-RM-1L-PEMBRO-CHEMO

Regimen

Pembrolizumab + 5-FU + platinum (HNSCC R/M, 1L; PD-L1 CPS ≥1)

Drugs + NSZU

Pembrolizumab (DRUG-PEMBROLIZUMAB) 200 mg IV (or 400 mg IV q6w) · Day 1 every 3 weeks (or q6w schedule), for up to 35 cycles (~2 years) or until progression / unacceptable toxicity · IV ⚠ NSZU — not for this indication
5-Fluorouracil (DRUG-5-FLUOROURACIL) 1000 mg/m² IV continuous infusion days 1-4 (96-hour infusion) · Days 1-4 of 21-day cycle, for 6 cycles · IV ⚠ NSZU — not for this indication
Cisplatin (DRUG-CISPLATIN) 100 mg/m² IV day 1 (preferred when ECOG 0-1, GFR ≥60, no neuropathy / ototoxicity / heart failure) · Day 1 of 21-day cycle, for 6 cycles · IV ⚠ NSZU — not for this indication
Carboplatin (DRUG-CARBOPLATIN) AUC 5 IV day 1 (substitute for cisplatin if contraindicated — GFR <60, neuropathy, hearing loss, congestive heart failure, or ECOG 2) · Day 1 of 21-day cycle, for 6 cycles (in lieu of cisplatin) · IV ⚠ NSZU — not for this indication

Reason

Current-line alternative presented for HCP consideration

Aggressive plan

Indication

IND-LARYNGEAL-RM-1L-PEMBRO-MONO-CPS-HIGH

Regimen

Pembrolizumab monotherapy (HNSCC R/M, 1L; PD-L1 CPS ≥20)

Drugs + NSZU

Pembrolizumab (DRUG-PEMBROLIZUMAB) 200 mg IV q3w (or 400 mg IV q6w) · Day 1 every 3 weeks (or q6w), for up to 35 cycles (~2 years) or until progression / unacceptable toxicity · IV ⚠ NSZU — not for this indication

Reason

Current-line alternative presented for HCP consideration

Standard plan

Indication

IND-LARYNGEAL-RM-1L-EXTREME

Regimen

EXTREME (cetuximab + cisplatin/carboplatin + 5-FU; HNSCC R/M, 1L)

Drugs + NSZU

Cetuximab (DRUG-CETUXIMAB) Loading 400 mg/m² IV day 1; then 250 mg/m² IV weekly · Loading dose week 1; weekly maintenance through chemotherapy and beyond as monotherapy until progression / toxicity · IV ⚠ NSZU — not for this indication
Cisplatin (DRUG-CISPLATIN) 100 mg/m² IV day 1 (preferred when ECOG 0-1, GFR ≥60, no neuropathy / ototoxicity / heart failure) · Day 1 of 21-day cycle, for up to 6 cycles · IV ⚠ NSZU — not for this indication
Carboplatin (DRUG-CARBOPLATIN) AUC 5 IV day 1 (substitute for cisplatin if contraindicated — GFR <60, neuropathy, hearing loss, congestive heart failure, or ECOG 2) · Day 1 of 21-day cycle, for up to 6 cycles (in lieu of cisplatin) · IV ⚠ NSZU — not for this indication
5-Fluorouracil (DRUG-5-FLUOROURACIL) 1000 mg/m² IV continuous infusion days 1-4 (96-hour infusion) · Days 1-4 of 21-day cycle, for up to 6 cycles · IV ⚠ NSZU — not for this indication

Reason

Current-line alternative presented for HCP consideration

Pre-treatment investigations

Investigations before treatment start · critical / standard / desired · merged across tracks

ID	Name	Priority	Category	Where to order	Needed for
TEST-CBC	Complete Blood Count with Differential	Critical	lab	—	local_therapy
TEST-CMP	Comprehensive Metabolic Panel	Critical	lab	—	local_therapy
TEST-PDL1-IHC	PD-L1 IHC (TPS for NSCLC)	Critical	—	CSD Lab ✓ (code TBC)	aggressive, standard
TEST-RENAL-FUNCTION-EGFR	Renal function with eGFR	Critical	lab	—	local_therapy
TEST-AUDIOMETRY	Audiometry	Standard	clinical_assessment	—	local_therapy
TEST-CT-NECK-THORAX-ABDOMEN-PELVIS	CT neck/thorax/abdomen/pelvis	Standard	imaging	—	local_therapy

Red flags — PRO / CONTRA aggressive

PRO-AGGRESSIVE

Triggers that push toward the aggressive track

Active or latent infection requiring resolution / prophylaxis before initiating cisplatin-based chemoradiation, cetuximab + RT, or pembrolizumab in HNSCC: HBsAg-positive (HBV reactivation on cytotoxic chemotherapy + checkpoint inhibitors), anti-HBc-positive (occult HBV on cetuximab — anti-EGFR class), HIV-positive (ART coordination, often comorbid in HPV-related HNSCC), or active TB.
Cetuximab — anti-EGFR mAb — has documented HBV reactivation reports (less than rituximab but non-zero); FDA label notes warning. Standard HBsAg + anti-HBc + anti-HBs serology pre-treatment; entecavir / tenofovir for HBsAg+. HIV-related…
RF-HNSCC-INFECTION-SCREENINGSRC-NCCN-HNSCC-2025SRC-ESMO-HNSCC-2020
Baseline organ dysfunction precluding standard cisplatin-based chemoradiation or pembrolizumab + 5-FU + cisplatin / cetuximab in head and neck squamous cell carcinoma: CrCl <60 mL/min (cisplatin contraindicated at full dose, switch to carboplatin or cetuximab), hearing loss / ototoxicity baseline (cisplatin contraindicated), LVEF <50% (5-FU cardiac risk), bilirubin >3× ULN (taxane / 5-FU metabolism), or severe peripheral neuropathy (cisplatin + taxane contraindicated).
Cisplatin-based CRT is the curative-intent standard (Intergroup 0099, TAX 324, EORTC 24891) but ~30% of HNSCC patients are cisplatin- ineligible at presentation due to age + organ dysfunction. CrCl <60: switch to carboplatin (RTOG 81-17…
RF-HNSCC-ORGAN-DYSFUNCTIONSRC-NCCN-HNSCC-2025SRC-ESMO-HNSCC-2020
Feature precluding larynx-preservation chemoradiation (RTOG 91-11 concurrent cisplatin + RT) as the preferred locally advanced treatment pathway, favoring primary total laryngectomy instead: radiographic cartilage invasion / destruction, tumor extension through cartilage into extralaryngeal soft tissue, substantial (≥1 cm) invasion of the tongue base, or pretreatment laryngeal dysfunction (severe aspiration, or feeding-tube / tracheostomy dependence) indicating a non-functional larynx that organ- preservation therapy would not salvage.
STUB pending Clinical Co-Lead sign-off (CHARTER §6.1). Larynx- preservation-candidacy gate for locally advanced laryngeal SCC — routes ALGO-LARYNGEAL-1L step 5 to primary total laryngectomy instead of RTOG 91-11 concurrent chemoradiation…
RF-LARYNGEAL-POOR-PRESERVATION-CANDIDACYSRC-NCCN-HNSCC-2025SRC-RTOG-9111-FORASTIERE-2003

CONTRA-AGGRESSIVE

Hard contraindications to escalation

What NOT to do

Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity

Local therapy plan (IND-LARYNGEAL-LA-1L-CRT)

Do not offer concurrent cisplatin CRT to patients with cartilage invasion, a non-functional larynx, or other RF-LARYNGEAL-POOR-PRESERVATION-CANDIDACY features — primary total laryngectomy is preferred.
Do not initiate high-dose cisplatin without baseline audiometry and renal function assessment.
Do not omit post-treatment surveillance laryngoscopy — salvage laryngectomy remains available for recurrence.

Local therapy plan (IND-LARYNGEAL-EARLY-GLOTTIC-1L-RT)

Do not omit MDT discussion of the TLM alternative before defaulting to RT — the choice is preference/expertise-driven, not oncologically forced.
Do not skip baseline voice/laryngeal function assessment before treatment.

Local therapy plan (IND-LARYNGEAL-EARLY-GLOTTIC-1L-TLM)

Do not perform TLM without adequate transoral exposure and visualization of tumor margins — poor exposure increases positive-margin risk.
Do not omit MDT discussion of definitive RT as an equally effective alternative.

Local therapy plan (IND-LARYNGEAL-LA-1L-TOTAL-LARYNGECTOMY)

Do not proceed to total laryngectomy without MDT discussion of the larynx-preservation CRT alternative when the patient is a candidate.
Do not omit voice-rehabilitation counseling and referral before surgery.
Do not omit postoperative pathology review (margins, extranodal extension) when determining adjuvant RT dose / need for concurrent chemotherapy.

Standard plan (IND-LARYNGEAL-RM-1L-PEMBRO-CHEMO)

Do NOT initiate immunotherapy without confirmed PD-L1 CPS testing on representative tumor tissue (biopsy preferred).
Do NOT use cisplatin in patients with GFR <60, gr ≥2 hearing loss, gr ≥2 neuropathy, or significant CHF — switch to carboplatin AUC 5.
Do NOT continue pembrolizumab through gr ≥3 immune-related AE without high-dose corticosteroid initiation + multidisciplinary irAE management.

Aggressive plan (IND-LARYNGEAL-RM-1L-PEMBRO-MONO-CPS-HIGH)

Do NOT use pembrolizumab monotherapy in CPS <20 — chemo-IO or EXTREME is preferred.
Do NOT use pembrolizumab monotherapy as 1L in rapidly progressive / visceral-crisis disease — early progression risk before IO kinetics establish.
Do NOT continue pembrolizumab through gr ≥3 immune-related AE without high-dose corticosteroid initiation + multidisciplinary irAE management.

Standard plan (IND-LARYNGEAL-RM-1L-EXTREME)

Do not prescribe EXTREME without HPV testing — HPV+ status does not change EXTREME selection in the recurrent setting, but is prognostically relevant.
Do not skip baseline GFR / audiogram / neuropathy assessment before cisplatin — carboplatin is an acceptable substitute if there are any contraindications.
Do not use cetuximab without premedication at the first infusion — anaphylaxis risk (alpha-gal IgE).

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Local therapy plan

Induction · Cisplatin concurrent with definitive RT (larynx-preservation CRT; RTOG 91-11)

21-day cycles × 3 cycles (days 1, 22, 43) concurrent with 70 Gy / 35 fx definitive RT

Standard plan

Induction · Pembrolizumab + 5-FU + platinum (HNSCC R/M, 1L; PD-L1 CPS ≥1)

21-day cycles × 6 cycles of chemotherapy backbone, then pembrolizumab maintenance up to 35 cycles total (~2 years)

Aggressive plan

Induction · Pembrolizumab monotherapy (HNSCC R/M, 1L; PD-L1 CPS ≥20)

21-day cycles × Up to 35 cycles (~2 years) or until progression

Standard plan

Induction · EXTREME (cetuximab + cisplatin/carboplatin + 5-FU; HNSCC R/M, 1L)

21-day cycles × Up to 6 cycles of chemotherapy backbone; cetuximab continued weekly as monotherapy until progression or unacceptable toxicity

MDT brief

Discussion questions (2, 0 blocking)

OQ-LDH-CURRENT
What is the current LDH? Marker of tumor burden and transformation.
LDH is part of the prognostic indices of indolent lymphomas.
→ hematologist
OQ-BIOMARKER-PDL1-CPS
What is the status of PD-L1 Combined Positive Score (CPS) (BIO-PDL1-CPS)? It is required by track(s): IND-LARYNGEAL-RM-1L-PEMBRO-CHEMO, IND-LARYNGEAL-RM-1L-PEMBRO-MONO-CPS-HIGH, IND-LARYNGEAL-RM-1L-EXTREME. Expected value: CPS ≥1.
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ pathologist

MDT talk tree (3 steps)

#	Owner	Topic	Action
1	hematologist	Staging / disease burden	What is the current LDH? Marker of tumor burden and transformation.
2	pathologist	Biomarker status	What is the status of PD-L1 Combined Positive Score (CPS) (BIO-PDL1-CPS)? It is required by track(s): IND-LARYNGEAL-RM-1L-PEMBRO-CHEMO, IND-LARYNGEAL-RM-1L-PEMBRO-MONO-CPS-HIGH, IND-LARYNGEAL-RM-1L-EXTREME. Expected value: CPS ≥1.
3	clinical_pharmacist	Specialist review	Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.

Skills (recommended) — for consideration (1)

Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.

Data quality

Usable with caveats. No critical default-track gap was found, but the MDT should review the listed caveats before final sign-off.

Biomarker coverage: 0/1 known (0%), 1 missing, 0 default-track gaps
Unevaluated RedFlags: RF-LARYNGEAL-POOR-PRESERVATION-CANDIDACY

Missing biomarker	Label	MDT owner	Default track	Required by	Next action
`BIO-PDL1-CPS`	PD-L1 Combined Positive Score (CPS)	pathologist	no	IND-LARYNGEAL-RM-1L-PEMBRO-CHEMO, IND-LARYNGEAL-RM-1L-PEMBRO-MONO-CPS-HIGH, IND-LARYNGEAL-RM-1L-EXTREME	Verify result, method, specimen, and report date before sign-off. Expected/constraint: CPS ≥1

Technical MDT skill metadata (1/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Cellular therapy specialist (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Clinical pharmacist	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Hematologist / oncohematologist	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Infectious disease / hepatology	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Medical oncologist (solid-tumor chemotherapist)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Molecular geneticist / molecular oncologist	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Palliative care	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Pathologist (general)	`pathologist`	v0.1.0	2026-04-25	pathology
Primary care / family physician	`primary_care`	v0.1.0	2026-04-25	primary_care
Psycho-oncologist	`psychologist`	v0.1.0	2026-04-25	psychosocial
Radiation oncologist	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Radiologist	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Social worker / case manager	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Surgical oncologist	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Transplant specialist (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-EXTREME-VERMORKEN-2008: Platinum-based chemotherapy plus cetuximab in head and neck cancer (2008)
SRC-KEYNOTE-048-BURTNESS-2019: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) (2019)
SRC-NCCN-HNSCC-2025: NCCN Clinical Practice Guidelines — Head and Neck Cancers (2025.v3)
SRC-RTOG-9111-FORASTIERE-2003: Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer (2003)

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-07-15.

NCT	Title	Phase	Status	Sponsor	UA	Signals
NCT04671667	Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma	PHASE2	RECRUITING	National Cancer Institute (NCI)	—	Single country
NCT01810913	Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer	PHASE2 / PHASE3	RECRUITING	National Cancer Institute (NCI)	—	—
NCT06662058	Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation	NA	RECRUITING	Emory University	—	Single country
NCT06914999	Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer	EARLY_PHASE1	RECRUITING	Emory University	—	Small N (<50) Single country
NCT06579248	Intraoral Hypothermia Device for Preserving Taste During Radiation	EARLY_PHASE1	RECRUITING	Henry Ford Health System	—	Small N (<50) Single country
NCT06648096	Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)	PHASE1 / PHASE2	RECRUITING	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	—	Small N (<50) Surrogate endpoint only
NCT03114462	Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer	PHASE1	RECRUITING	M.D. Anderson Cancer Center	—	Phase 1 only Small N (<50) Single country
NCT03556228	VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma	PHASE1 / PHASE2	RECRUITING	VM Oncology, LLC	—	—
NCT06532279	Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer	PHASE2	RECRUITING	NRG Oncology	—	Single country
NCT02734537	Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery	PHASE2	RECRUITING	ECOG-ACRIN Cancer Research Group	—	Surrogate endpoint only Single country

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).

Option	UA registration	NSZU	Cost orientation	Access pathway
Local therapy plan Cisplatin concurrent with definitive RT (larynx-preservation CRT; RTOG 91-11) (REG-CISPLATIN-CONCURRENT-RT-LARYNX)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Local therapy plan — No regimen components on this track — availability unknown	— unknown	— unknown	₴-? — verify pathway	not recorded
Local therapy plan — No regimen components on this track — availability unknown	— unknown	— unknown	₴-? — verify pathway	not recorded
Local therapy plan — No regimen components on this track — availability unknown	— unknown	— unknown	₴-? — verify pathway	not recorded
Standard plan Pembrolizumab + 5-FU + platinum (HNSCC R/M, 1L; PD-L1 CPS ≥1) (REG-PEMBRO-CHEMO-HNSCC-1L)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Aggressive plan Pembrolizumab monotherapy (HNSCC R/M, 1L; PD-L1 CPS ≥20) (REG-PEMBRO-MONO-HNSCC-1L)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Standard plan EXTREME (cetuximab + cisplatin/carboplatin + 5-FU; HNSCC R/M, 1L) (REG-EXTREME-HNSCC)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Trial · NCT04671667 Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT01810913 Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06662058 Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06914999 Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06579248 Intraoral Hypothermia Device for Preserving Taste During Radiation No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06648096 Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT03114462 Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT03556228 VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06532279 Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT02734537 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-07-15.

plan_id: PLAN-VERIFIED-LARYNGEAL-L1-LARYNGEAL_LA_1L_CRT-V1 | version: 1 | generated: 2026-07-15T13:33:22.933521+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.